Deficits in a sustained attention task following nicotine withdrawal in rats

Psychopharmacology
Mohammed Shoaib, L Bizarro

Abstract

Behavioural consequences of spontaneous and antagonist-precipitated withdrawal from nicotine upon performance of rats were compared alongside non-nicotinic antagonists in the 5-choice serial reaction time task (5-CSRTT). Male hooded Lister rats were trained to detect and respond to brief flashes of light presented every 15 s in one of five holes until a stable level of performance was achieved. Surgical removal of osmotic minipumps from rats having received nicotine (3.16 mg/kg per day base SC) chronically for 7 days produced marked deficits in performance. Compared to saline-treated controls, deficits were apparent 10 h and 16 h following nicotine abstinence; the percentage of omission errors increased concomitantly with modest decreases in response accuracy. Tests conducted 34 h and 106 h post-withdrawal indicated a progressive and complete recovery in attention performance, respectively. In another experiment, following the exposure to the same nicotine regime, administration of the competitive nicotine receptor antagonist dihydro-beta-erythroidine precipitated immediate deficits in performance that were greater than those observed in saline-treated subjects. Methyllycaconitine, an alpha(7) nicotinic receptor antagonist fail...Continue Reading

References

Nov 1, 1992·Pharmacology, Biochemistry, and Behavior·D H MalinO B Wilson
Jan 1, 1990·Psychopharmacology·I HindmarchN Sherwood
Jan 1, 1989·Psychopharmacology·R M KeenanD J Anton
Jul 1, 1989·Pharmacology, Biochemistry, and Behavior·W A CorrigallK M Coen
Jun 1, 1989·Drug and Alcohol Dependence·F R SnyderJ E Henningfield
Mar 1, 1986·Archives of General Psychiatry·J R Hughes, D Hatsukami
Jan 1, 1983·Pharmacology & Therapeutics·K Wesnes, D M Warburton
Jan 1, 1984·Psychopharmacology·W H Loke, C J Meliska
Jan 1, 1993·Psychopharmacology·T M GrossM R Rosenblatt
Jan 1, 1993·Psychopharmacology·D H MalinO B Wilson
Apr 1, 1994·British Journal of Pharmacology·M ShoaibD J Balfour
Feb 21, 1998·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·A MarkouG F Koob
May 20, 1998·Nature·M P Epping-JordanA Markou
Jul 21, 1998·Annals of the New York Academy of Sciences·T W RobbinsB J Everitt
Sep 2, 1998·Psychopharmacology·E D Levin, B B Simon
Sep 2, 1998·Psychopharmacology·N R Mirza, I P Stolerman
Sep 11, 1999·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·B E HildebrandG G Nomikos
Feb 7, 2001·Psychopharmacology·N R Mirza, I P Stolerman
Nov 10, 2000·Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco·S L BellS J Heishman
Aug 28, 2001·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·M ErnstE D London
Nov 6, 2001·Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco·A Markou, N E Paterson
Feb 14, 2002·Pharmacology, Biochemistry, and Behavior·P J Kenny, A Markou
Feb 14, 2002·Pharmacology, Biochemistry, and Behavior·D H Malin
Jan 1, 1991·Journal of Psychopharmacology·A C Parrott, G Roberts
Jun 1, 1998·Annals of the New York Academy of Sciences·T W RobbinsB J Everitt

❮ Previous
Next ❯

Citations

Aug 29, 2006·Psychopharmacology·Francesco MussoGeorg Winterer
Jul 17, 2013·Biochemical Pharmacology·Rogier B Poorthuis, Huibert D Mansvelder
Aug 27, 2013·Neurobiology of Learning and Memory·Thomas J Gould, Prescott T Leach
Dec 19, 2012·The Pharmacogenomics Journal·R L AshareC Lerman
Aug 22, 2006·Schizophrenia Bulletin·Amy C ChessDavid J Bucci
Jan 7, 2010·Current Opinion in Psychiatry·Georg Winterer
Aug 11, 2007·Nature Reviews. Drug Discovery·Caryn LermanWilliam A Corrigall
Apr 9, 2014·Expert Opinion on Drug Discovery·Rebecca L Ashare, Heath D Schmidt
Jul 11, 2014·ACS Chemical Neuroscience·Rick A Bevins, Joyce Besheer
Jun 10, 2015·Neuroscience and Biobehavioral Reviews·F Scott HallJared W Young
Sep 22, 2006·Physiology & Behavior·N M W J de BruinA A H P Megens
Jul 26, 2011·Biochemical Pharmacology·Michael Paolini, Mariella De Biasi
Feb 3, 2015·Journal of the Experimental Analysis of Behavior·Imme RoewerJan Peters
Oct 1, 2013·European Journal of Pharmacology·Todd M Hillhouse, Adam J Prus
Jan 11, 2005·Physiology & Behavior·D V Poltavski, T Petros
Jun 1, 2008·Current Protocols in Pharmacology·Guy A Higgins, Nathalie Breysse
Jul 5, 2008·Psychopharmacology·Jennifer L Perry, Marilyn E Carroll
Sep 12, 2017·Current Protocols in Pharmacology·Guy A Higgins, Leo B Silenieks
Apr 28, 2016·Journal of Psychoactive Drugs·Brandon A BaiamonteSarah J Ford
Apr 24, 2021·Journal of Psychopharmacology·Ranjithkumar ChellianAdriaan W Bruijnzeel
Apr 28, 2021·Progress in Neuro-psychopharmacology & Biological Psychiatry·Luisa PonzoniMariaelvina Sala
Apr 20, 2021·Frontiers in Psychiatry·Spencer Bell, Brett Froeliger

❮ Previous
Next ❯

Related Concepts

Related Feeds

Attention Disorders

Attention is involved in all cognitive activities, and attention disorders are reported in patients with various neurological diseases. Here are the latest discoveries pertaining to attention disorders.